SCHEMBL2194014

SCHEMBL2194014

CC(O)(C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ncc(-c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@](C)(O)c4ccccc4)cc3)o2)cc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 2/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
F2 P00734 2/20 0.45
SMO Q99835 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
EP300 Q09472 1/20 0.43
CREBBP Q92793 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194019 1.00 ALDH1A1 (0.46) ALDH1A1MAPK1KDM4ENPC1MEN1
SCHEMBL12487606 1.00 ALDH1A1 (0.46) ALDH1A1MAPK1KDM4ENPC1MEN1
SCHEMBL14647983 0.89 F2 (0.50) ALDH1A1MAPK1KDM4ENPC1F2
SCHEMBL13571817 0.89 F2 (0.50) ALDH1A1MAPK1KDM4ENPC1F2
SCHEMBL12491697 0.89 F2 (0.50) ALDH1A1MAPK1KDM4ENPC1F2
SCHEMBL2176369 0.89 F2 (0.50) ALDH1A1MAPK1KDM4ENPC1F2
SCHEMBL2176361 0.89 F2 (0.50) ALDH1A1MAPK1KDM4ENPC1F2
SCHEMBL13571431 0.88 ALDH1A1 (0.50) ALDH1A1MAPK1KDM4ENPC1MEN1
SCHEMBL14723789 0.86 KCNH2 (0.55) ALDH1A1MAPK1KDM4ENPC1F2
SCHEMBL13571673 0.84 ALDH1A1 (0.47) ALDH1A1MAPK1KDM4ENPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519506-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-11-07 EP claimed
US-20110294819-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US claimed
WO-2011082077-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-07-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294819-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, GTF3C1 ALDH1A1 3778/4885MAPK1 1678/4885KDM4E 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.